Washington tightens biotech investment
Last week, US Treasury Secretary Scott Bessent added biotechnology to an outbound investment screening programme, placing a broad range of transactions involving “countries of concern”, including China, under greater scrutiny. Restricted transactions include acquiring equity stakes and forming joint ventures.
Bessent said the measures were intended to prevent adversaries from using US investment to develop critical technologies that threaten national security. David Zhang, an analyst at policy research firm Trivium China, said the draft rules would make it much harder for Chinese biotech firms to attract direct US investment or enter joint ventures.
Licensing remains a bright spot
China’s biopharmaceutical industry has risen sharply in recent years. According to the National Development and Reform Commission, out-licensing deals involving China-developed innovative drugs have reached US$130 billion this year, approaching the full-year total for 2025.








